VCEL (Vericel) Other Current Liabilities: $0.1 Mil (As of Mar. 2026)


VCEL Vericel Corp VCEL
81 GF Score
Price $45.07
GF Value $54.29
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Vericel Other Current Liabilities?

Vericel VCEL -2.51% 81 Other Current Liabilities is $0.1 Mil as of Mar. 2026. GuruFocus rates VCEL with a GF Score™ of 81/100 and a GF Value™ of $54.29 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Vericel's other current liabilities for the quarter that ended in Mar. 2026 was $0.1 Mil.

Vericel's quarterly other current liabilities increased from Sep. 2025 ($12.0 Mil) to Dec. 2025 ($14.3 Mil) but then declined from Dec. 2025 ($14.3 Mil) to Mar. 2026 ($0.1 Mil).

Vericel's annual other current liabilities increased from Dec. 2023 ($13.3 Mil) to Dec. 2024 ($13.6 Mil) and increased from Dec. 2024 ($13.6 Mil) to Dec. 2025 ($14.3 Mil).

Vericel Other Current Liabilities Related Terms

Vericel Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Vericel's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vericel Other Current Liabilities Chart

Vericel Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.92 10.27 13.26 13.58 14.26

Vericel Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.09 11.12 12.00 14.26 0.12
VCEL
81GF Score
Vericel Corp VCEL
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vericel Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.1 Mil mean?
Vericel (VCEL) has a Other Current Liabilities of $0.1 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vericel.
Is Vericel's Other Current Liabilities too high?
Vericel's current Other Current Liabilities is $0.1 Mil. Overall, Vericel has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's Other Current Liabilities compare to NRIX and MLYS?
Vericel's Other Current Liabilities of $0.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vericel. Vericel's current Other Current Liabilities is $0.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $54.29, compared to a current price of $45.07 — trading 17% below its estimated fair value. The current Other Current Liabilities is $0.1 Mil. Vericel's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Vericel (VCEL), the current Other Current Liabilities is $0.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vericel (VCEL) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of $45.07 is trading 17% below its estimated GF Value™ of $54.29. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for VCEL:

  • Other Current Liabilities: $0.1 Mil
  • GF Value™: $54.29 vs. price of $45.07 (17% below fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges ATQP:Germany
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
81GF Score

Get the complete analysis for VCEL

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$45.07
Price
$54.29
GF Value